Inherited CDK12 Mutations Drive Aggressive Prostate Cancer, Study Finds
“What’s striking is that every patient we identified with this inherited mutation had already developed metastatic disease by the time they were diagnosed,” said Dr. Alexander Wyatt, who holds the roles of associate professor of urologic sciences in the UBC faculty of medicine alongside UBC President’s Excellence Chair in Precision Oncology.
University of British Columbia researchers published a study in Cancer Discovery identifying a previously unrecognized inherited form of prostate cancer linked to rare genetic mutations.
Most tumors develop as genetic alterations accumulate within cells during a person’s lifetime. Approximately 5% to 10% of cancers instead stem from inherited mutations passed across generations, according to findings reported by ScienceDaily. Well-known examples include BRCA1 and BRCA2 gene variants, which elevate risks for breast, ovarian, pancreatic, and prostate malignancies.
The newly identified hereditary risk involves the CDK12 gene. Researchers examined genetic information from more than 4,500 people with aggressive prostate cancer and discovered five unrelated men carrying inherited CDK12 mutations. Every one of those patients developed metastatic prostate cancer between ages 44 and 62, meaning the disease had spread beyond the prostate gland.
Scientists previously assumed that harmful CDK12 alterations arose spontaneously inside tumor cells rather than passing from a parent. To confirm the inherited link, investigators checked patient tumors for a specific pattern of genetic damage tied to lost CDK12 function.
“The tumors provided us with a genetic signature that pointed directly back to CDK12,” said Dr. Sofie Tolmeijer, lead author and postdoctoral fellow in the Wyatt lab, as reported by SciTechDaily. “It gave us compelling evidence that these inherited mutations were playing a direct role in causing their cancer.”
Adding CDK12 to hereditary prostate cancer panels
Inherited CDK12 mutations appear exceptionally rare, occurring in approximately one out of every 1,000 people with aggressive prostate cancer. Even at that low frequency, researchers estimate the variant affects hundreds of families worldwide. Finding a single carrier creates an opportunity to screen relatives before tumors develop or spread.
The research team recommends incorporating CDK12 into standard hereditary prostate cancer testing panels. Because clinical technology to spot these mutations already exists, expanding current screening protocols remains straightforward and cost-effective. “One of the most exciting aspects of this discovery is that we already have the technology needed to act on it,” Wyatt said.
Investigators also found potential links between inherited CDK12 variants and ovarian cancer. Several men in the study had relatives with histories of ovarian cancer, and researchers identified an additional ovarian cancer patient carrying an inherited CDK12 mutation whose tumor displayed the identical genetic signature. Further studies will clarify whether screening recommendations for ovarian cancer should change as a result.
Financial backing for the research was provided by the Prostate Cancer Foundation, Terry Fox Research Institute, Canadian Cancer Society, Canadian Institutes of Health Research, Michael Smith Health Research BC, U.S. National Institutes of Health, and the BC Cancer Foundation.
“While this mutation is extremely rare, the discovery could be lifesaving for the families who carry it,” Tolmeijer said.
Founded through provincial legislation in 1908, the University of British Columbia opened its doors in 1915 after absorbing McGill University College and awarded its first degrees in 1916. UBC hosts TRIUMF, Canada’s national particle and nuclear physics laboratory with the world’s largest cyclotron, and jointly established North America’s first Max Planck Institute with the Max Planck Society.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
- South Korea and Mexico Sign Seafood Hygiene Agreement to Strengthen Import Safety Controls
- Google Quantum AI Demonstrates Contextuality With 98.3% Success Rate Up to 105 Qubits
- Study Finds Retatrutide Reduces Knee Pain (time.news)
- AI Prioritises 16 Cancer Drug Candidates Targeting Bacterial DnaK (archyde.com)